Background and aims: A recent study reported that a nonsynonymous SNP rs2241880 (c.898A >G, p.Thr300Ala) within ATG16L1 confers susceptibility to Crohn's disease (CD). We analyzed ATG16L1 c.898A > G in three independent European inflammatory bowel disease (IBD) cohorts from Germany, Hungary and the Netherlands. ava i l a b l e a t w w w. s c i e n c e d i r e c t . c o m
Introduction
Crohn's disease (CD) is thought to result from an aberrant immune response towards bacteria of fecal origin in a genetically susceptible host. The characterization of the genetic background in CD is emerging rapidly, especially by genome-wide association studies. Using this approach, a nonsynonymous SNP (rs2241880) in the ATG16L1 gene leading to a threonine by alanine exchange in codon 300 (c.898A > G, p.
Thr300Ala) was recently associated with CD, but not with ulcerative colitis (UC).
1 ATG16L1 encodes a protein involved in processing of intracellular bacteria, and mouse orthologue localizes to the autophagic isolation membrane during autophagosome formation. 2 Although the precise function of human ATG16L1 is currently unknown, an aberrant ATG16L1 protein might result in defective bacterial detection and thus play a role in CD pathogenesis. This is supported by the function of the most established genetic risk factor for CD, CARD15, which constitutes an intracellular receptor for bacterial recognition. 3 Interestingly, the pioneer study detected statistical interactions between ATG16L1 and CARD15.1.
A disturbed epithelial barrier is suggested to be crucially involved in development and course of CD. This barrier dysfunction is believed to be genetically determined. We have recently reported that the c.3020insC CARD15 variant might only explain part of this genetic basis 4 and thus other genetic variants must be involved.
We formulated the following aims of our study: First, can we replicate the association of c.898A > G ATG16L1 to CD by investigating three European IBD populations? Second, can we provide further evidence for statistical interactions between c.898A > G and CARD15 variants? Third, is c.898A >G associated with a distinct phenotype of CD? Fourth, does c.898A > G contribute to increased gastrointestinal permeability in CD?
2. Materials and methods
Patients
Patients with the diagnosis of CD or UC were included in the study based upon clinical, endoscopic, radiological, and histological findings according to standardized criteria. 5 All studies were approved by the responsible ethic committees of all three institutions and informed consent was obtained from each participant.
IBD patients were recruited from the following tertiary referral centers: In total, 489 Caucasian IBD patients (310 with CD and 179 with UC) were recruited from the Charité Berlin (Campus Mitte and Campus Virchow). In addition, 147 patients with CD and 117 patients with UC from the 1st Department of Medicine, Faculty of Medicine, University of Szeged, Hungary, were included. Among the 147 CD patients, 137 were Caucasians and 10 patients were from the Roma minority (Gypsy).
Lastly, we enrolled 157 CD patients from the Department of Gastroenterology and Hepatology at the Radboud University Nijmegen Medical Center, the Netherlands.
Unrelated and healthy subjects from Germany (n = 285), Hungary (n = 207) and the Netherlands (n = 215) served as controls.
Clinical characteristics of IBD patients
Clinical data of IBD patients were obtained through retrospective collection from the patients clinical charts prior to genotyping. The following data of CD patients were obtained from Germany and Hungary: age, age at diagnosis, gender, familial or spontaneous disease (familial disease was considered when one first-or second-degree relative was diagnosed with IBD), smoking habits (current smoking, or history of smoking, or never smoked), disease localization (according to the Montreal classification 5 ), disease pattern, extraintestinal manifestations (type 1 peripheral arthralgia, affections of eyes or skin, primary sclerosing cholangitis), surgical interventions with respect to indication (stenotic or fistulizing disease) and type (e.g. ileocecal resection, small or large bowel resection, repeated surgical intervention). Among the CD patients from Nijmegen, the Netherlands, the following data had been recorded: age, age at diagnosis, gender, familial or spontaneous disease, disease localization and behavior, perianal disease, and surgery for CD.
The following data of UC patients were obtained: age at diagnosis, gender, familial or spontaneous disease, smoking habits, disease localization (proctitis, left side colitis, pancolitis), extraintestinal manifestations, type and date of surgery, and occurrence of colorectal cancer. p.T300A variant and fluorescence resonance energy transfer (FRET) probes were synthesized based on the published nucleotide sequence (GenBank #NT_005120.15). Primer sequences used for PCR were: 5′-ATTTgTCTTTATgTTATTTCTTAggAgACg-3′ (forward) and 5′-TgCAggCCTAgAAAggACC-3′ (reverse). We performed PCR using 0.5 U AmpliTaq Gold (Applied Biosystems), 400 μM dNTPs, 1.5 mM MgCl 2 , 0.5 μM of forward primer and 0.1 μM of reverse primer in a final volume of 25 μl. The reaction mix was denatured at 95°C for 12 min followed by 40 cycles of denaturation at 95°C for 20 s, annealing at 56°C for 40 s, elongation at 72°C for 90 s, and a final extension step for 2 min at 72°C in a thermocycler.
The detection of the mutant allele was carried out by melting curve analysis with FRET probes in the LightCycler 480 instrument (Roche Diagnostics). The probes were designed complementary to the mutant allele. For detection of the c.898A > G (p.T300A) alteration the sequence of the anchor fluoresceine labeled probe was 5′-gTAgCTggTACCCTCACTTCTTTACCAgA-FLandthatofthesensorLightCyclerRed 610 labeled probe was 5′-LC610-CCAggATgAg[C]ATCCACATTgT-phosphate.
All genetic alterations are numbered at the cDNA level, indicated by a "c." before the number. Position + 1 corresponds to the A of the ATG translation initiation codon located at nucleotide 1155 in the NM_030803.
6 ATG16L1 mRNA reference sequence. All amino acid changes are indicated by a "p". In each LightCycler run, patients as well as control samples were analyzed. Control subjects were tested for Hardy-Weinberg equilibrium.
Genotyping for CARD15 variants
Genotyping for the three common CARD15 variants (p. Arg702Trp, p.Gly908Arg, c.3020insC) were performed in patients with IBD from Germany and Hungary as described previously. 6 Genotyping for CARD15 variants in CD patients from Nijmegen has been described elsewhere. 7 The analysis stratifies for these three common CARD15 variants.
Measurement of gastroduodenal and intestinal permeability
Gastroduodenal and intestinal permeability has been measured using a triple-sugar-test in CD patients (n =105) from the German cohort as described before. 4 The test is based in principle on the measurement of the urinary excretion of orally administered non-metabolized sugar molecules. Sucrose served as marker for gastroduodenal permeability and the lactulose/mannitol ratio (permeability index, PI for intestinal permeability). We used a total of n = 96 healthy volunteers (female 56, male 40; age: 35 ± 12 years) as controls. Range of normal permeability was calculated by means ± 2 SD of controls. At time of testing, all German CD patients were in remission (as defined by CDAI (CD activity index) b 150).
Statistical analysis
For statistical analysis we adopted the following strategy.
First, we compared allele frequencies of c.898A > G between patients (IBD, CD and UC) and controls using 2 × 2 contingency tables. For pooled analysis of all three cohorts, CochranMantel-Haenszel test (two-sided) as implemented in R was applied (The R Project for Statistical Computing.http:// www.r-project.org/). For the individual cohorts, allele frequencies were compared by Fisher's exact test (twosided). Odds ratio and confidence intervals were estimated using allele frequencies in 2 × 2 contingency tables. To detect statistical interactions between CARD15 variants and Table 2 (UC). The effect of the CARD15 status on the clinical course of CD was not the focus of the current study, but observations in our three cohorts have shown that the c.3020insC variant is a risk factor for stenotic disease behavior and increases the need for surgical interventions in CD. [6] [7] [8] Overall, the clinical presentation of IBD was similar among all three populations in terms of age, gender, familial disease, smoking, disease localization, behavior, and surgery.
Distribution of the c.898A > G ATG16L1 variant in IBD patients and controls
We started to investigate the frequencies of the c.898A N G variant in a total of 919 patients with inflammatory bowel variants and the ATG16L1 c.898A >G alteration, we stratified for c.898A > G in respect to the CARD15 genotype (Table 4) . We defined a CARD15 risk genotype as being either heterozygous or homozygous/compound heterozygous for either p. Arg702Trp, p.Gly908Arg, or c.3020insC. We also combined the data from all three cohorts to increase the power to detect statistical interactions, since CD patients from all cohorts display similar frequencies of CARD15 risk carriers (Table 2 ). In summary, we did not observe any statistical interactions between ATG16L1 c.898A >G and CARD15 variants.
Effect of the c.898A > G variant on the clinical course of Crohn's disease
We then used the clinical and demographical data of the IBD patients to perform detailed genotype phenotype analysis. In the CD cohorts from Germany and the Netherlands, no significant association was found depending on c.898A N G genotype. In Hungarian CD patients, the G allele was negatively associated with stenotic disease behavior (p = 0.02, data not shown). However, this association could not be confirmed in German and Dutch CD patients. No other significant findings were made. In UC, no clinical parameter correlated to c.898A N G genotype.
Effect of the c.898A >G variant on gastroduodenal and intestinal permeability in CD
Gastroduodenal and intestinal permeability was determined in German CD (n = 105) patients using a triple-sugar-test. At time of testing, all CD patients were in remission (CDAI b 150). An increased gastroduodenal and intestinal permeability was found in 37.1% (39/105) and 43.9% (46/ Genotypes of c.898A N G in German, Hungarian and Dutch CD patients stratified for CARD15 mutations; CARD15+ (−): at least one (no) mutant allele within CARD15 variants (p. Arg702Trp, p.Gly908Arg, c.3020insC); Absolute numbers are illustrated. Allele frequencies were compared in 2 × 2 contingency tables using the ⁎Cochran-Mantel-Haenszel test for pooled analysis of all three cohorts, and the #Fisher's exact test for the individual cohort.
Published studies with respect to c.898A N G genotyping in CD patients. For the studies by Prescott 11 and Yamazaki 12 OR and 95% confidence intervals were calculated according to the c.898A N G genotype distribution as reported in the corresponding publication.
105) of CD patients, respectively. There was no association between the c.898A > G genotype and an increased gastroduodenal or intestinal permeability (data not shown).
Discussion
Two recent genome wide association studies identified new genetic alterations that are associated with IBD 9 and CD. 1 First, Duerr and colleagues found that a p.Arg308Gln variant within IL23R that protects from both CD and UC. 9 We analyzed this genotype in the same IBD cohorts included in the current study, and we were able to confirm the association in all three cohorts (Büning et al., 2007, in press ). Second, Hampe and colleagues identified a c.898A > G (p.T300A) variant within ATG16L1 to be associated with CD. 1 Upon analysis of three large and independent IBD cohorts, we were able to confirm their findings and indeed establish that c.898A > G is a susceptibility factor for CD, but not UC. We found a significant association of Table 5 ). Replication has so far been exclusively performed in UK samples. 10, 11 In contrast lack of association was reported in CD patients from Japan. 12 However, this underscores the distinct genetic background of CD in Japan. This reminds us of studies with the CARD15 variants in Japanese, were the gene frequency is very different from the Western-European population. 13 In agreement with the pioneer study and another UK (Oxford) study, 1,10 we did not observe an association to UC but in contrast to a very recent English study that did find a modest but significant association. 11 These data suggest that the influence of ATG16L1 on UC isif at all-weaker than on CD.
We did not detect a phenotype association to the c.898A N G genotype. An association to ileal disease was reported in one study from the UK 11 which we cannot replicate in our study. Our lack of association to a distinct subphenotype is in agreement with two other reports. 1, 10 We could not observe statistical interaction between CARD15 and ATG16L1 c.898A >G. This is in contrast to the initial report by Hampe and colleagues where a modest but significant association was found. However we cannot exclude that an analysis with larger sample sizes will actually detect such an association and confirms the findings from the pioneer study. Our observations are in line with the findings from two very recent studies in which also no statistical interactions between CARD15 and ATG16L1 c.898A >G could be established. 10, 11 Our study demonstrates that ATG16L1
c.898A >G is a CD risk factor in the absence of CARD15 alterations. We did not detect any association between altered gastrointestinal permeability in CD and the c.898A N G genotype. However, the small sample size of CD patients with increased gastrointestinal permeability limits this analysis and we cannot exclude that other variants within ATG16L1 might be involved in any epithelial barrier alterations. The p.Arg318Gln IL23R variant does also not contribute to this epithelial barrier defect (Büning, 2007, in press ). Therefore, the genetic background of the increased gastrointestinal permeability in CD remains tentative at the moment.
At present it can only be speculated how ATG16L1
c.898A >G contributes to CD. ATG16L1 encodes a protein that has been shown to be a part of the autophagosome pathway. Autophagy delivers cytoplasmic constituents for lysosomal degradation. By targeting intracellular pathogens for degradation, the autophagosome pathway has been shown to mediate an innate immune response to bacteria and viruses. 14 Moreover, autophagic degradation links the innate with the adaptive immune system through delivering antigens for MHC class II presentation. 15 Although the role of autophagy in chronic inflammation needs to be elucidated, it is conceivable that ATG16L1 malfunction might be an important aspect in CD pathogenesis. The pioneer study observed ATG16L1 expression in different organs such as colon, spleen, leukocytes, prostate, and kidney. 1 Interestingly, no difference in ATG16L1 expression was found when colonic biopsies from CD patients and controls were compared. Furthermore, the c.898A > G genotype did not influence ATG16L1 expression at both protein and cDNA level. Thus, further studies are needed to elucidate the function of ATG16L1 in order to evaluate its role in CD pathogenesis.
In 
